Limits...
Development of a Functional Biomarker for Use in Cell-Based Therapy Studies in Seropositive Rheumatoid Arthritis

View Article: PubMed Central - PubMed

ABSTRACT

This study tested the hypothesis that an ex vivo T-cell suppression assay could estimate response to novel cell-based therapy for rheumatoid arthritis (RA). Results showed multipotent adult progenitor cell products suppressed RA effector T cells. The study demonstrated the feasibility of using suppressor assays to detect biological effects of cell-based therapy in RA and suggests these effects are dose-dependent.

No MeSH data available.


Related in: MedlinePlus

CCM improved Treg function. Suppression assays of effector T cells (Teffs) using combination of 50% by volume CCM and Tregs at ratios of Teff to Tregs varying from 1:1 to 1:4. Bars represent the mean values. Abbreviations: CCM, multipotent adult progenitor cell-conditioned medium; HD1–HD3, healthy donors specific to each experiment; RA1–RA4, distinct rheumatoid arthritis patients specific to this experiment; Treg, T-regulatory cell.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4835254&req=5

Figure 3: CCM improved Treg function. Suppression assays of effector T cells (Teffs) using combination of 50% by volume CCM and Tregs at ratios of Teff to Tregs varying from 1:1 to 1:4. Bars represent the mean values. Abbreviations: CCM, multipotent adult progenitor cell-conditioned medium; HD1–HD3, healthy donors specific to each experiment; RA1–RA4, distinct rheumatoid arthritis patients specific to this experiment; Treg, T-regulatory cell.

Mentions: We further hypothesized that in vivo, MAPCs and MSCs might act directly and indirectly on Teffs by also improving Treg function. To determine whether CCM improved Treg function, we performed suppression assays using 50% CCM, a concentration that suboptimally suppressed Teffs (Fig. 2). Using CCM alone, suppression of Teffs (mean ± SEM) was 59% ± 6% (Fig. 3). Addition of Tregs increased suppression to 90% ± 3% (1:1 Tregs to Teffs), 84% ± 3% (1:2 Tregs to Teffs), and 71% ± 6% (1:4 Tregs to Teffs).


Development of a Functional Biomarker for Use in Cell-Based Therapy Studies in Seropositive Rheumatoid Arthritis
CCM improved Treg function. Suppression assays of effector T cells (Teffs) using combination of 50% by volume CCM and Tregs at ratios of Teff to Tregs varying from 1:1 to 1:4. Bars represent the mean values. Abbreviations: CCM, multipotent adult progenitor cell-conditioned medium; HD1–HD3, healthy donors specific to each experiment; RA1–RA4, distinct rheumatoid arthritis patients specific to this experiment; Treg, T-regulatory cell.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4835254&req=5

Figure 3: CCM improved Treg function. Suppression assays of effector T cells (Teffs) using combination of 50% by volume CCM and Tregs at ratios of Teff to Tregs varying from 1:1 to 1:4. Bars represent the mean values. Abbreviations: CCM, multipotent adult progenitor cell-conditioned medium; HD1–HD3, healthy donors specific to each experiment; RA1–RA4, distinct rheumatoid arthritis patients specific to this experiment; Treg, T-regulatory cell.
Mentions: We further hypothesized that in vivo, MAPCs and MSCs might act directly and indirectly on Teffs by also improving Treg function. To determine whether CCM improved Treg function, we performed suppression assays using 50% CCM, a concentration that suboptimally suppressed Teffs (Fig. 2). Using CCM alone, suppression of Teffs (mean ± SEM) was 59% ± 6% (Fig. 3). Addition of Tregs increased suppression to 90% ± 3% (1:1 Tregs to Teffs), 84% ± 3% (1:2 Tregs to Teffs), and 71% ± 6% (1:4 Tregs to Teffs).

View Article: PubMed Central - PubMed

ABSTRACT

This study tested the hypothesis that an ex vivo T-cell suppression assay could estimate response to novel cell-based therapy for rheumatoid arthritis (RA). Results showed multipotent adult progenitor cell products suppressed RA effector T cells. The study demonstrated the feasibility of using suppressor assays to detect biological effects of cell-based therapy in RA and suggests these effects are dose-dependent.

No MeSH data available.


Related in: MedlinePlus